Early Mental Health Challenges After Cancer Diagnosis Linked to Increased Mortality Risk
A recent study sheds light on the critical association between newly diagnosed mental health disorders (MHDs) within the first year after a cancer diagnosis and all-cause mortality. The research also characterized patterns of early MHD emergence, highlighting a significant area for improved patient care.
Prevalence and Impact of Mental Health Disorders
Many individuals diagnosed with cancer experience considerable emotional distress, with prior research indicating that up to one-third may develop MHDs during their cancer journey. While previous studies suggested MHDs increase morbidity and mortality in this population, they often faced limitations such as small sample sizes or reliance on self-reported symptoms. This new study aimed to address the shortage of large-scale analyses evaluating clinically verified MHDs and their link to mortality, particularly those manifesting after a cancer diagnosis.
Study Methodology
The study analyzed data from a diverse, multi-institutional cohort within a statewide academic health system. It included 371,897 patients aged 18 and older who were newly diagnosed with cancer at University of California hospitals between January 2013 and January 2023. Patient data, encompassing cancer and MHD diagnoses, age, sex, race, ethnicity, comorbidity, and psychotropic medication prescriptions, were obtained from anonymized electronic health records using ICD-10 codes. New MHDs (psychotic, mood, or anxiety disorders) diagnosed within 12 months of cancer diagnosis and new psychotropic medication prescriptions were evaluated. All-cause mortality was the primary outcome, measured from the cancer diagnosis date using the California Death Certificate Registry. Multivariable Cox regression models adjusted for various factors were used for analysis.
Key Findings
The mean age of patients was 62.1 years; nearly half were female, and the majority were White. The median follow-up was 28.2 months, during which 23.1% of patients died, with a 5-year overall survival rate of 72%.
A notable 10.6% of patients developed a new MHD within a year of cancer diagnosis, predominantly generalized anxiety or major depressive disorder. Over one-third of those with new MHDs received psychotropic medications, and nearly one in four cancer patients was prescribed benzodiazepines.
The incidence of new MHDs sharply increased approximately three months before cancer diagnosis and peaked within the first six months after diagnosis. Cancers with lower survival rates (e.g., pancreatic cancer) showed a strong association with new MHDs, while those with better outcomes (e.g., nonmelanoma skin cancer) showed a lesser association.
Patients who developed a new MHD within the first 12 months faced a substantially higher risk of death during the 12 to 35 months after diagnosis (adjusted hazard ratio of approximately 1.5).
This risk decreased over time. The mortality risk was even higher for those prescribed new psychotropic medications during the early period (adjusted hazard ratio of approximately 2.7 in the 12–35 month interval), though this also lessened in later years. These findings suggest early mental health challenges after cancer diagnosis are linked to poorer short-term survival.
Conclusions and Limitations
The study concluded that patients developing a mental health condition after a cancer diagnosis and receiving psychotropic medication are at a heightened risk of all-cause mortality. However, the study design does not establish causation; psychotropic medication use may indicate greater psychiatric severity, advanced cancer burden, or other underlying factors, rather than a direct harmful effect of the medications. Reliance on electronic health record diagnostic codes may also introduce documentation bias.
The findings highlight a critical need for integrated care models, including routine mental health screening, timely intervention, and ongoing support, to potentially mitigate excess mortality risk and improve overall outcomes for cancer patients.